PCOS (Polycystic Ovary Syndrome)
Conditions
Keywords
platelet-rich plasma, oocyte maturation, in vitro maturation
Brief summary
In vitro maturation is a long-studied technique used to obtain mature oocytes outside the human body. However, this method can increase the risk of ovarian hyperstimulation syndrome (OHSS), particularly in patients with polycystic ovarian syndrome (PCOS). Culture media supplemented with platelet-rich plasma (PRP) has previously shown promise for improving oocyte maturation. This study examined the potential utility of allogeneic PRP supplementation to increase the maturation of germinal vesicle (GV)-stage oocytes collected from PCOS patients who underwent controlled ovarian stimulation. Supplementation with 5% PRP was found to support oocyte maturation under controlled ovarian stimulation. Further investigations are required to refine the use of PRP without controlled ovarian stimulation in clinical IVM protocols that may be beneficial for PCOS patients.
Interventions
An initial pilot experiment tested three different concentrations of PRP supplementation (5%, 25%, and 50%)
Sponsors
Gadjah Mada University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Prospective cohort study using PRP-supplementation in culture media
Eligibility
Sex/Gender
FEMALE
Age
30 Years to 41 Years
Healthy volunteers
No
Inclusion criteria
* Immature oocytes at the germinal vesicle (GV) stage * Oocytes obtained from patients fulfilling clinical and laboratory diagnostic criteria for PCOS, defined by the presence of at least two of the following three characteristics: clinical hyperandrogenism and/or biochemical hyperandrogenemia, ovulatory dysfunction (oligomenorrhea or anovulation), and polycystic ovarian morphology (≥12 follicles measuring 2-9 mm in each ovary on ultrasonography) * Oocytes collected from patients undergoing ovarian stimulation using the same ovarian stimulation protocol. * Oocytes obtained from patients with primary infertility * Oocytes obtained from treatment-naive patients with PCOS.
Exclusion criteria
\- Oocytes obtained from patients with comorbid conditions, including cancer, congenital adrenal hyperplasia, Cushing's syndrome, premature ovarian failure (POF) or premature ovarian insufficiency, liver disorders, kidney disease, cardiovascular disease, diabetes mellitus (type 1 or type 2), and patients receiving steroid therapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Optimal PRP Concentration | After 24 hours of culture incubation | A concentration of 5% PRP was optimal rather than concentrations of 25% and 50% (cells are clumping and also associated with morphological abnormalities, such as cytoplasmic vacuolization, irregular perivitelline space, and abnormal polar bodies) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Oocyte maturation rate | After 24 hours of culture incubation | After optimation, this study used PRP with concentration 5% tu supplementing IVM culture media. The 5% PRP supplementation group showed a significantly higher rate of oocyte maturation compared to the control group (non-PRP group) |
| Oocyte morphological quality and fertilization rate | After 24 hours of culture incubation | The PRP 5% group had a higher average TOS than the control group (non-PRP) and the fertilization rate in the PRP 5% group was 80% descriptively |
Countries
Indonesia
Outcome results
None listed